GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (NAS:KPTI) » Definitions » Profitability Rank

Karyopharm Therapeutics (Karyopharm Therapeutics) Profitability Rank : 3 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Karyopharm Therapeutics Profitability Rank?

Karyopharm Therapeutics has the Profitability Rank of 3. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Karyopharm Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -112.03%. As of today, Karyopharm Therapeutics's Piotroski F-Score is 3.


Competitive Comparison of Karyopharm Therapeutics's Profitability Rank

For the Biotechnology subindustry, Karyopharm Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Profitability Rank falls into.



Karyopharm Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Karyopharm Therapeutics has the Profitability Rank of 3. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Karyopharm Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-37.808 / 33.747
=-112.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Karyopharm Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

Karyopharm Therapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank


Karyopharm Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Karyopharm Therapeutics (Karyopharm Therapeutics) Business Description

Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Executives
Richard A. Paulson director, officer: President and CEO 85 WELLS AVENUE, NEWTON MA 02459
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Michael Mason officer: EVP, CFO, Treasurer 300 3RD STREET, CAMBRIDGE MA 02142
Michael Mano officer: SVP, General Counsel&Secretary 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Sohanya Roshan Cheng officer: SVP Sales & Commercial Ops C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459
Zhen Su director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Stuart Poulton officer: EVP, Chief Development Officer 85 WELLS AVENUE, NEWTON MA 02459
Reshma Rangwala officer: EVP & Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Stephen Mitchener officer: SVP, Chief Business Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Ran Frenkel officer: EVP, WW Development Operations C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Jatin Shah officer: EVP, Chief Medical Officer C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459
Sharon Shacham officer: C.S.O & Pres. of Res & Develop C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Kauffman director, officer: President, C.E.O., C.M.O. C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Peter Honig director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037